Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan

Kenta Nio, Daijiro Higashi, Hozumi Kumagai, Shuji Arita, Tsuyoshi Shirakawa, Koji Nakashima, Yoshihiro Shibata, Motohiro Esaki, Tatsuya Manabe, Shuntaro Nagai, Takashi Ueki, Michitaka Nakano, hiroshi ariyama, Hitoshi Kusaba, Minako Hirahashi, Yoshinao Oda, Taito Esaki, Kenji Mitsugi, Kitaro Futami, Koichi Akashi & 1 others Eishi Baba

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Chemotherapy for advanced colitis-associated colorectal cancer (CAC) has been insufficiently evaluated. The goal of this study was to clarify the efficacy and safety of chemotherapy for CAC in Japan. CAC patients who were treated with chemotherapy between 2005 and 2015 were retrospectively examined. Twenty-nine patients (median age, 48 years; 23 men) were assessed. Eighteen patients had ulcerative colitis, and 11 had Crohn's disease. Three ulcerative colitis and four Crohn's disease patients were in the active disease phase. Primary tumors were located in the rectum/anus (n = 16), the left colon (n = 9), or the right colon (n = 4). Palliative or adjuvant chemotherapy was performed in 13 and 16 patients, respectively. First-line palliative chemotherapy regimens were as follows: fluorouracil, leucovorin, and oxaliplatin (FOLFOX; n = 6), FOLFOX + bevacizumab (n = 3), and others (n = 4). Adjuvant chemotherapy regimens were S-1 (n = 7), oxaliplatin-based (n = 4) and others (n = 5). In palliative chemotherapy, the objective response rate was 15%, and the median progression-free survival and overall survival were 182 and 315 days, respectively. In adjuvant chemotherapy, the 5-year relapse-free survival rate was 78%. Grade 3/4 adverse events (AEs) were observed in 16 patients (55%). Active and remission inflammatory bowel disease patients suffered grade 3/4 nonhematological AEs at an incidence of 71 and 23%, respectively (P< 0.01). Dose reduction was required in 11 patients (38%), eight of whom required it for hematological AEs. Adjuvant chemotherapy for CAC exhibited sufficient efficacy, whereas modest efficacy was shown for palliative chemotherapy for CAC. AEs, particularly nonhematological AEs, were closely associated with disease activity of colitis.

元の言語英語
ページ(範囲)457-463
ページ数7
ジャーナルAnti-Cancer Drugs
27
発行部数5
DOI
出版物ステータス出版済み - 6 1 2016

Fingerprint

Colitis
Colorectal Neoplasms
Japan
Safety
Drug Therapy
oxaliplatin
Adjuvant Chemotherapy
Ulcerative Colitis
Crohn Disease
Colon
Leucovorin
Anal Canal
Inflammatory Bowel Diseases
Rectum
Fluorouracil
Disease-Free Survival
Survival Rate
Recurrence
Survival
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

これを引用

Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan. / Nio, Kenta; Higashi, Daijiro; Kumagai, Hozumi; Arita, Shuji; Shirakawa, Tsuyoshi; Nakashima, Koji; Shibata, Yoshihiro; Esaki, Motohiro; Manabe, Tatsuya; Nagai, Shuntaro; Ueki, Takashi; Nakano, Michitaka; ariyama, hiroshi; Kusaba, Hitoshi; Hirahashi, Minako; Oda, Yoshinao; Esaki, Taito; Mitsugi, Kenji; Futami, Kitaro; Akashi, Koichi; Baba, Eishi.

:: Anti-Cancer Drugs, 巻 27, 番号 5, 01.06.2016, p. 457-463.

研究成果: ジャーナルへの寄稿記事

Nio, K, Higashi, D, Kumagai, H, Arita, S, Shirakawa, T, Nakashima, K, Shibata, Y, Esaki, M, Manabe, T, Nagai, S, Ueki, T, Nakano, M, ariyama, H, Kusaba, H, Hirahashi, M, Oda, Y, Esaki, T, Mitsugi, K, Futami, K, Akashi, K & Baba, E 2016, 'Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan', Anti-Cancer Drugs, 巻. 27, 番号 5, pp. 457-463. https://doi.org/10.1097/CAD.0000000000000338
Nio, Kenta ; Higashi, Daijiro ; Kumagai, Hozumi ; Arita, Shuji ; Shirakawa, Tsuyoshi ; Nakashima, Koji ; Shibata, Yoshihiro ; Esaki, Motohiro ; Manabe, Tatsuya ; Nagai, Shuntaro ; Ueki, Takashi ; Nakano, Michitaka ; ariyama, hiroshi ; Kusaba, Hitoshi ; Hirahashi, Minako ; Oda, Yoshinao ; Esaki, Taito ; Mitsugi, Kenji ; Futami, Kitaro ; Akashi, Koichi ; Baba, Eishi. / Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan. :: Anti-Cancer Drugs. 2016 ; 巻 27, 番号 5. pp. 457-463.
@article{8658c3a901a1415eb3c16226715fbb92,
title = "Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan",
abstract = "Chemotherapy for advanced colitis-associated colorectal cancer (CAC) has been insufficiently evaluated. The goal of this study was to clarify the efficacy and safety of chemotherapy for CAC in Japan. CAC patients who were treated with chemotherapy between 2005 and 2015 were retrospectively examined. Twenty-nine patients (median age, 48 years; 23 men) were assessed. Eighteen patients had ulcerative colitis, and 11 had Crohn's disease. Three ulcerative colitis and four Crohn's disease patients were in the active disease phase. Primary tumors were located in the rectum/anus (n = 16), the left colon (n = 9), or the right colon (n = 4). Palliative or adjuvant chemotherapy was performed in 13 and 16 patients, respectively. First-line palliative chemotherapy regimens were as follows: fluorouracil, leucovorin, and oxaliplatin (FOLFOX; n = 6), FOLFOX + bevacizumab (n = 3), and others (n = 4). Adjuvant chemotherapy regimens were S-1 (n = 7), oxaliplatin-based (n = 4) and others (n = 5). In palliative chemotherapy, the objective response rate was 15{\%}, and the median progression-free survival and overall survival were 182 and 315 days, respectively. In adjuvant chemotherapy, the 5-year relapse-free survival rate was 78{\%}. Grade 3/4 adverse events (AEs) were observed in 16 patients (55{\%}). Active and remission inflammatory bowel disease patients suffered grade 3/4 nonhematological AEs at an incidence of 71 and 23{\%}, respectively (P< 0.01). Dose reduction was required in 11 patients (38{\%}), eight of whom required it for hematological AEs. Adjuvant chemotherapy for CAC exhibited sufficient efficacy, whereas modest efficacy was shown for palliative chemotherapy for CAC. AEs, particularly nonhematological AEs, were closely associated with disease activity of colitis.",
author = "Kenta Nio and Daijiro Higashi and Hozumi Kumagai and Shuji Arita and Tsuyoshi Shirakawa and Koji Nakashima and Yoshihiro Shibata and Motohiro Esaki and Tatsuya Manabe and Shuntaro Nagai and Takashi Ueki and Michitaka Nakano and hiroshi ariyama and Hitoshi Kusaba and Minako Hirahashi and Yoshinao Oda and Taito Esaki and Kenji Mitsugi and Kitaro Futami and Koichi Akashi and Eishi Baba",
year = "2016",
month = "6",
day = "1",
doi = "10.1097/CAD.0000000000000338",
language = "English",
volume = "27",
pages = "457--463",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan

AU - Nio, Kenta

AU - Higashi, Daijiro

AU - Kumagai, Hozumi

AU - Arita, Shuji

AU - Shirakawa, Tsuyoshi

AU - Nakashima, Koji

AU - Shibata, Yoshihiro

AU - Esaki, Motohiro

AU - Manabe, Tatsuya

AU - Nagai, Shuntaro

AU - Ueki, Takashi

AU - Nakano, Michitaka

AU - ariyama, hiroshi

AU - Kusaba, Hitoshi

AU - Hirahashi, Minako

AU - Oda, Yoshinao

AU - Esaki, Taito

AU - Mitsugi, Kenji

AU - Futami, Kitaro

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Chemotherapy for advanced colitis-associated colorectal cancer (CAC) has been insufficiently evaluated. The goal of this study was to clarify the efficacy and safety of chemotherapy for CAC in Japan. CAC patients who were treated with chemotherapy between 2005 and 2015 were retrospectively examined. Twenty-nine patients (median age, 48 years; 23 men) were assessed. Eighteen patients had ulcerative colitis, and 11 had Crohn's disease. Three ulcerative colitis and four Crohn's disease patients were in the active disease phase. Primary tumors were located in the rectum/anus (n = 16), the left colon (n = 9), or the right colon (n = 4). Palliative or adjuvant chemotherapy was performed in 13 and 16 patients, respectively. First-line palliative chemotherapy regimens were as follows: fluorouracil, leucovorin, and oxaliplatin (FOLFOX; n = 6), FOLFOX + bevacizumab (n = 3), and others (n = 4). Adjuvant chemotherapy regimens were S-1 (n = 7), oxaliplatin-based (n = 4) and others (n = 5). In palliative chemotherapy, the objective response rate was 15%, and the median progression-free survival and overall survival were 182 and 315 days, respectively. In adjuvant chemotherapy, the 5-year relapse-free survival rate was 78%. Grade 3/4 adverse events (AEs) were observed in 16 patients (55%). Active and remission inflammatory bowel disease patients suffered grade 3/4 nonhematological AEs at an incidence of 71 and 23%, respectively (P< 0.01). Dose reduction was required in 11 patients (38%), eight of whom required it for hematological AEs. Adjuvant chemotherapy for CAC exhibited sufficient efficacy, whereas modest efficacy was shown for palliative chemotherapy for CAC. AEs, particularly nonhematological AEs, were closely associated with disease activity of colitis.

AB - Chemotherapy for advanced colitis-associated colorectal cancer (CAC) has been insufficiently evaluated. The goal of this study was to clarify the efficacy and safety of chemotherapy for CAC in Japan. CAC patients who were treated with chemotherapy between 2005 and 2015 were retrospectively examined. Twenty-nine patients (median age, 48 years; 23 men) were assessed. Eighteen patients had ulcerative colitis, and 11 had Crohn's disease. Three ulcerative colitis and four Crohn's disease patients were in the active disease phase. Primary tumors were located in the rectum/anus (n = 16), the left colon (n = 9), or the right colon (n = 4). Palliative or adjuvant chemotherapy was performed in 13 and 16 patients, respectively. First-line palliative chemotherapy regimens were as follows: fluorouracil, leucovorin, and oxaliplatin (FOLFOX; n = 6), FOLFOX + bevacizumab (n = 3), and others (n = 4). Adjuvant chemotherapy regimens were S-1 (n = 7), oxaliplatin-based (n = 4) and others (n = 5). In palliative chemotherapy, the objective response rate was 15%, and the median progression-free survival and overall survival were 182 and 315 days, respectively. In adjuvant chemotherapy, the 5-year relapse-free survival rate was 78%. Grade 3/4 adverse events (AEs) were observed in 16 patients (55%). Active and remission inflammatory bowel disease patients suffered grade 3/4 nonhematological AEs at an incidence of 71 and 23%, respectively (P< 0.01). Dose reduction was required in 11 patients (38%), eight of whom required it for hematological AEs. Adjuvant chemotherapy for CAC exhibited sufficient efficacy, whereas modest efficacy was shown for palliative chemotherapy for CAC. AEs, particularly nonhematological AEs, were closely associated with disease activity of colitis.

UR - http://www.scopus.com/inward/record.url?scp=84954419240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954419240&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000338

DO - 10.1097/CAD.0000000000000338

M3 - Article

VL - 27

SP - 457

EP - 463

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -